Immunic Inc (IMUX)
1.25
0.00 (0.00%)
USD |
NASDAQ |
May 17, 16:00
1.25
0.00 (0.00%)
After-Hours: 20:00
Immunic Free Cash Flow (Quarterly): -24.00M for March 31, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | -24.00M |
December 31, 2023 | -14.19M |
September 30, 2023 | -17.36M |
June 30, 2023 | -20.00M |
March 31, 2023 | -19.62M |
December 31, 2022 | -15.10M |
September 30, 2022 | -13.67M |
June 30, 2022 | -15.79M |
March 31, 2022 | -20.69M |
December 31, 2021 | -23.70M |
September 30, 2021 | -17.62M |
June 30, 2021 | -29.02M |
March 31, 2021 | -12.96M |
December 31, 2020 | -13.99M |
September 30, 2020 | -11.97M |
June 30, 2020 | -9.282M |
March 31, 2020 | -11.03M |
December 31, 2019 | -6.29M |
September 30, 2019 | -5.989M |
June 30, 2019 | -11.00M |
March 31, 2019 | -5.324M |
December 31, 2018 | -4.653M |
September 30, 2018 | -13.35M |
Date | Value |
---|---|
June 30, 2018 | -12.54M |
March 31, 2018 | -13.22M |
December 31, 2017 | -10.03M |
September 30, 2017 | -9.586M |
June 30, 2017 | -10.28M |
March 31, 2017 | -11.18M |
December 31, 2016 | -9.221M |
September 30, 2016 | -8.161M |
June 30, 2016 | -8.867M |
March 31, 2016 | -10.08M |
December 31, 2015 | -9.339M |
September 30, 2015 | -12.35M |
June 30, 2015 | -16.42M |
March 31, 2015 | -14.18M |
December 31, 2014 | -10.44M |
September 30, 2014 | -11.51M |
June 30, 2014 | -10.11M |
March 31, 2014 | -10.17M |
December 31, 2013 | -10.44M |
September 30, 2013 | -8.723M |
June 30, 2013 | -6.292M |
March 31, 2013 | -4.675M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-29.02M
Minimum
Jun 2021
-5.989M
Maximum
Sep 2019
-15.66M
Average
-14.65M
Median
Free Cash Flow (Quarterly) Benchmarks
Kymera Therapeutics Inc | -46.99M |
Insmed Inc | -188.71M |
SELLAS Life Sciences Group Inc | -10.76M |
Skye Bioscience Inc | -4.711M |
Leap Therapeutics Inc | -15.52M |